德琪医药-B(06996)股东将股票由渣打银行（香港）转入高盛（亚洲）证券 转仓市值4.82亿港元

Group 1 - The core point of the article is that Dechra Pharmaceuticals-B (06996) has transferred shares from Standard Chartered Bank (Hong Kong) to Goldman Sachs (Asia) Securities, with a market value of HKD 482 million, representing 9.74% of the total shares [1] - On the same day, Dechra Pharmaceuticals-B announced that its internally developed Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 received breakthrough therapy designation from the National Medical Products Administration (NMPA) in China for the treatment of patients with CLDN18.2 positive, HER2 negative unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma who have previously received at least two treatments [1]